Carregant...
uPAR: a beacon of malignancy?
Discriminating between benign and malignant disease is a pivotal diagnostic issue in the care of women with pelvic masses. Soluble forms of urokinase plasminogen activator receptor (uPAR) represent a promising new tool in the development of a discriminatory biomarker panel that can influence patient...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2008
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2587046/ https://ncbi.nlm.nih.gov/pubmed/18794069 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-1557 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|